Author

Patricia Alfonso

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 3 Research Focus:protein folding & dynamics· 2 Assay:proteomics· 2 Research Focus:benchmarking· 1 Research Focus:differential expression· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Ana CorrioneroiD· 4 shared Niall PrendivilleiD· 3 shared Sandra RöhmiD· 3 shared Stefan KnappiD· 3 shared Andreas KrämeriD· 2 shared Benedict‐Tilman BergeriD· 2 shared Daniela S. KrauseiD· 2 shared Hayuningbudi Saraswati· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBiochemistry

Ana CorrioneroORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Kinetic Fingerprints as Mechanistic and Clinical Roadmaps Across KIT Activation States

Ana Corrionero, Niall Prendiville, Tatiana Cazorla, María Baena-Nuevo, Sandra Röhm, Emilio Camafeita, Stefan Knapp, Patricia Alfonso

This paper introduces kinetic fingerprints to evaluate KIT inhibitors, showing that residence time and dissociation rates predict clinical success and resistance.

ChemMedChem · Jun 3, 2026Peer-reviewedBiochemistry

Protein-ligand binding kinetics are primarily controlled by the protein, not the ligand.

Bharath Srinivasan, Ana Corrionero, Marco Barone, Patricia Alfonso, Niall Prendiville, Tatiana Cazorla, Anza Suneer Rahiyanath, Adrian Whitty, Peter J. Tonge

The paper analyzes 4,311 protein-small-molecule interactions to show that binding kinetics are mainly controlled by protein dynamics, not ligand structure.

bioRxiv · May 22, 2026 · PreprintBiochemistry

Covalent targeting leads to the development of LIMK1 isoform-selective inhibitors

Sebastian Mandel, Thomas Hanke, Niall Prendiville, María Baena-Nuevo, Lena M. Berger, Frederic Farges, Martin P. Schwalm, Benedict‐Tilman Berger, Andreas Krämer, Lewis Elson, Hayuningbudi Saraswati, Kamal Rayees Abdul Azeez, Verena Dederer, Sebastian Mathea, Ana Corrionero, , Stefan Knapp

This study develops a covalent LIMK1 inhibitor that selectively targets a unique cysteine, enabling isoform-specific studies of LIMK1 function.

Journal of Medicinal Chemistry · Jul 2, 2025Peer-reviewedBiochemistry

Repurposing of the RIPK1 selective benzooxazepin-4-one scaffold for the development of a type-III LIMK1/2 inhibitor

Sebastian Mandel, Thomas Hanke, Sebastian Mathea, Deep Chatterjee, Hayuningbudi Saraswati, Benedict‐Tilman Berger, Martin P. Schwalm, Satoshi Yamamoto, Michiko Tawada, Terufumi Takagi, Mahmood Ahmed, Sandra Röhm, Ana Corrionero, Patricia Alfonso, Maria Baena, , Stefan Knapp

The paper repurposes a benzoxazepinone scaffold originally designed for RIPK1 inhibition to develop a novel type-III LIMK1/2 inhibitor with high selectivity.

ACS Chemical Biology · Apr 14, 2025Peer-reviewedBiochemistry